Macomics and the Institute of Oncology Research (IOR, Switzerland) Announce Macrophage Scientific Collaboration in Prostate Cancer Drug Development
19 juin 2024 04h00 HE
|
Macomics Limited
Laboratory of Prof. Andrea Alimonti at IOR (Institute of Oncology Research, Bellinzona, Switzerland) and Macomics to bring together expertise on myeloid-derived suppressor cells in prostate cancer...
Macomics Announces Appointment of Simon Dew as New Chief Business Officer
10 juin 2024 04h00 HE
|
Macomics Limited
Macomics continues to expand its leadership team to accelerate the development of first-in-class macrophage-targeted therapiesSimon Dew brings over 25 years of experience in pharmaceutical business...
Macomics and IFOM (the AIRC Institute of Molecular Oncology) Announce Macrophage Scientific Collaboration
13 mai 2024 04h00 HE
|
Macomics Limited
Laboratory of Prof. Massimiliano Pagani at IFOM (the AIRC Institute of Molecular Oncology) and Macomics to bring together expertise on T-cell biology, ex-vivo tumoroids and macrophagesThe...
Macomics Unveils its Lead First-in-Class Anti-Pan-LILRB Monoclonal Antibody Programme with Positive Pre-clinical Data Presented at AACR 2024
11 avr. 2024 04h00 HE
|
Macomics Limited
Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancerData presented at AACR 2024 shows MACO-355 is...
Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director
19 oct. 2023 04h00 HE
|
Macomics Limited
EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent...
Macomics Expands in Edinburgh with Move to Roslin Innovation Centre and Announces Appointment of Professor Paul Crocker to SAB
29 sept. 2023 04h00 HE
|
Macomics Limited
EDINBURGH and CAMBRIDGE, United Kingdom, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh into...
Macomics Presents its ENIGMAC™ Discovery Platform for Gene to Function Target Validation of Novel Macrophage Therapies at AACR
17 avr. 2023 13h30 HE
|
Macomics Limited
EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom, April 17, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery has presented data demonstrating the power of its...
Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer
23 mars 2023 02h00 HE
|
Macomics Limited
Worldwide drug discovery collaboration agreement with Ono to develop new antibody drugs against a novel macrophage target of interest in immuno-oncologyMacomics will develop antibody candidates...
Scientists at Macomics and University of Edinburgh Map Out the Discoveries of a New Class of Tumour Associated Immune Cells Revealing Opportunities to Develop Novel Cancer Treatments
17 févr. 2023 05h19 HE
|
Macomics Limited
Publication in Nature Reviews Cancer based on data gained over 50 years of discovery research in the area of macrophage biologyReveals future prospects for developing precision medicines to modulate...